A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy

Trial Profile

A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Alemtuzumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CARE-MS-II
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 19 Jun 2018 Results (NCT00530348, NCT00548405 and NCT00930553) examining the association between lymphocyte repopulation patterns and clinical/MRI disease activity through 6 years presented at the 4th Congress of the European Academy of Neurology
    • 28 Oct 2017 Results of analysis providing updated pregnancy outcomes in alemtuzumab-treated female patients from the clinical development program trials (NCT00050778, [NCT00530348, NCT00548405, NCT00930553, NCT02255656) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 27 Jun 2017 Results of pooled analysis of NCT00530348, NCT00548405 and NCT00930553 trials assessing conversion from RRMS to SPMS presented at the 3rd Congress of the European Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top